ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting

    Glucocorticoid Adverse Effects – the Patient Perspective

    Rachel Black1, Susan M. Goodman2, Carlee Ruediger3, Susan Lester4, Sarah Mackie5 and Catherine Hill3, 1Department of Medicine, The University of Adelaide, Adelaide, Australia, 2Medicine, Hospital for Special Surgery, New York, NY, 3Medicine, The University of Adelaide, Adelaide, Australia, 4Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
  • Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting

    Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus

    Sharzad Emamikia1, Cidem Gentline2, Magnus Backheden3, Katerina Chatzidionysiou2, Laurent Arnaud4 and Ronald F. van Vollenhoven2,5, 1Department of Medicine, Karolinska Institute, Stockholm, Sweden, 2Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 3Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, 4Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands

    Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…
  • Abstract Number: 1199 • 2016 ACR/ARHP Annual Meeting

    A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium

    James Bluett1, Sally-Ann Owen1, Jonathan Massey2, Darren Plant2, Munir Pirmohamed3, Suzanne M.M. Verstappen4 and Anne Barton5,6, 1Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 3Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom

    Background/Purpose: Methotrexate (MTX) is associated with a rare but potentially life-threatening lung disease, MTX-pneumonitis (MTX-P). MTX-P is an idiosyncratic hypersensitivity reaction to MTX inducing inflammation,…
  • Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting

    Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study

    Jeffrey Curtis1, Fenglong Xie2, Lang Chen2 and Huifeng Yun3, 1Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL

    Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
  • Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting

    Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching

    Una E. Makris1,2, Carlos A. Alvarez2,3,4, Eric M. Mortensen2,4 and Ishak Mansi2,4, 1Rheumatology, UT Southwestern Medical Center, Dallas, TX, 2VA North Texas Health Care System, Dallas, TX, 3Texas Tech University Health Science Center, Dallas, TX, 4UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…
  • Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting

    Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty

    Hiroki Wakabayashi1, Masahiro Hasegawa2, Toshio Yamaguchi3, Yohei Naito4 and Akihiro Sudo5, 1Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, 2Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 3Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan, 4Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, 5Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan

    Background/Purpose:  Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…
  • Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting

    Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis

    Emily Fishman1, Kathryn H. Dao2 and John J. Cush3, 1Texas A&M HSC College of Medicine, Dallas, TX, 2Texas Health, Dallas, TX, 3Baylor Research Institute, Dallas, TX

    Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
  • Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting

    Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis

    Frank Buttgereit1, Jonna Amann2, Friederike Breitenfeldt3, Dörte Huscher4, Johannes WJ Bijlsma5 and Johannes WG Jacobs6, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 4Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, 5ARC, Amsterdam, Netherlands, 6Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
  • Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting

    Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs

    Delfina Bur1 and Humeira M. Badsha2, 1Dr. Humeira Badsha Medical Clinic, Dubai, United Arab Emirates, 2Rheumatology, Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates

    Background/Purpose:  Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…
  • Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting

    Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder

    Takuma Tsuzuki Wada1, Yuji Akiyama1 and Toshihide Mimura2, 1Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
  • Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting

    Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up

    Zulema Rosales1,2, Leticia Leon1, Alejandro Gomez-Gomez2, Lucía Arietti2, Esperanza Pato Cour2, José Luis Fernández Rueda1, Juan A Jover2 and Lydia Abasolo1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
  • Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting

    Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)

    Na Lu1, Sharan K. Rai2, Jeewoong Choi3 and Hyon K. Choi1, 1Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA

    Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
  • Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting

    Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Meghna Jani1, William G Dixon2, Lianne Kearsley-Fleet3, Ian N. Bruce4,5, Hector Chinoy6,7, Anne Barton6,8, Mark Lunt9, Kath Watson3, Deborah P.M. Symmons1, Kimme L. Hyrich3 and on behalf of the BSRBR-RA, 1Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 4Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 5Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 6Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 7NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 8NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 9Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom

    Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
  • Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting

    Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis

    Matthew J. Koster1, Cristian Labarca2, Cynthia S. Crowson3, Ashima Makol1, Steven R. Ytterberg4, Eric L. Matteson1 and Kenneth J. Warrington1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Rheumatology Division, Mayo Clinic, Rochester, MN

    Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
  • Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting

    Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register

    Pongthorn Narongroeknawin1, Wanruchada Katchamart2, Parawee Suwannalai3, Nuntana Kasitanon4, Tasanee Kitumnuaypong5, Ajanee Mahakkanukrauh6 and Boonjing Siripaitoon7, 1Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, 2Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, 3Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 5Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, 6Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, 7Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand

    Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology